TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06604442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flotufolastat (18F)
Description: Positron emission tomography (PET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piflufolastat (18F)
Description: Positron emission tomography (PET)
Study: NCT06656312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use ASUS EndoAim as an assistant software to perform colonoscopy
Description: Use ASUS EndoAim as an assistant software to perform colonoscopy
Study: NCT06659861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RV3278B-OS0386
Description: Cosmetic product to be applied twice a day on the face during the whole study

Intervention type: OTHER
Group type: OTHER
Intervention: RV4632A-RY1845
Description: Cosmetic product to be applied in the event of facial skin discomfort only
Study: NCT06664619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp/ABS
Description: Inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP
Description: Inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABS
Description: Inhalation powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder
Study: NCT06664801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC administered every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC administered every 3 weeks.
Study: NCT05611697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal bypass
Description: The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
Study: NCT04893837

Intervention type: DEVICE
Intervention: Standard care plus infrascans
Description: Hourly infrascans to detect expanding intracranial hematomas
Study: NCT04868240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent training program
Description: The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet.
Study: NCT05581719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Study: NCT05382858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters
Study: NCT05744492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivifrail multicomponent exercise program
Description: Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivifrail multicomponent exercise program
Description: Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session.
Study: NCT05735145

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel combined with platinum
Description: Adjuvant chemotherapy with paclitaxel combined with platinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel combined with platinum
Description: Adjuvant chemotherapy with paclitaxel combined with platinum
Study: NCT05438550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day high-dose Tegoprazan Dual Therapy (HDDT)
Description: 14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day high-dose Tegoprazan Dual Therapy (HDDT)
Description: 14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
Study: NCT05738252

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Phenotype
Description: Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Phenotype
Description: Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Phenotype
Description: Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
Study: NCT05945758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable resin composite technique.
Description: A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional layering technique
Description: the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
Study: NCT06244251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TU-LESS
Description: TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MPLS
Description: Patients with uterine who plan to receive MPLS for myomectomy
Study: NCT06664801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Background PAH Therapy
Description: Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
Study: NCT04956965

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac electro-mapping
Description: Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac electro-mapping
Description: Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
Study: NCT05874297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Access to enhanced Cook for your life website

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06049277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan techniques with manual traction
Description: group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie extension exercises with manual traction
Description: group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
Study: NCT05476718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo taping
Description: Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
Study: NCT05719597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP (Positive Expiratory Pressure)
Description: Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IS (Incentive spirometry)
Description: Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
Study: NCT05267002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal timing
Description: Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal timing
Description: Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
Study: NCT06549764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Aware of Mental Health
Description: Help-seeking and literacy increasing intervention
Study: NCT06666049

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: Gastric Ultrasound
Study: NCT06665932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic surgery is a minimally invasive form of surgical intervention that makes use of a three-dimensional coordinate system to locate small targets inside the body and to perform on them some action such as ablation, biopsy, lesion, injection, stimulation, implantation, radiosurgery, etc.
Study: NCT05521477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SLAB51
Description: One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
Study: NCT05339061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).
Description: Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch
Study: NCT06445179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Laparoscopic Hysterectomy
Description: The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureterolysis
Description: unilateral or bilateral ureterolysis with or without bilateral adnexectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureterolysis
Description: unilateral or bilateral ureterolysis with or without bilateral adnexectomy